Tests inhaled teicoplanin for staph infections in people with cystic fibrosis
Tests inhaled teicoplanin safety in people with cystic fibrosis and lasting staph infection.
Key facts
- Who runs it
- Azienda Ospedaliera Universitaria Integrata Verona
- Where
- Milan and Verona, ItalySee the 2 sites
- Registry title
- An open-label study to evaluate the safety and tolerability of inhaled Teicoplanin in the treatment of Staphylococcus aureus (including mrsa) infections in cystic fibrosis patients
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 12 people, planned
- Started
- 29 Nov 2024
- Planned end
- 16 Sept 2025
- Type of study
- Interventional
- Record updated
- 7 October 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with cystic fibrosis who have a long-lasting Staphylococcus aureus (including MRSA) lung infection. It tests the safety of inhaled teicoplanin.
- Age
- From 12 years up to 64 years.
- Sex
- Women and men can join.
- Disease stage
- Confirmed cystic fibrosis with persistent Staphylococcus aureus (including MRSA) infection: at least 3 positive sputum cultures in the 24 months before enrollment. Lung function (FEV1) between 50% and 90% of predicted.
- Earlier treatment
- Must not have had nebulized or systemic vancomycin or teicoplanin within 8 weeks before enrollment. People on Kaftrio+Kalydeco for less than 6 consecutive months cannot join.
Main reasons for not taking part
- Chronic Pseudomonas aeruginosa or Bulkholderia cepacia infection
- Past bronchoconstriction after inhaling a drug, or cannot tolerate inhaled products
- Allergy to glycopeptides, other antibiotics or any excipient
- Pregnant or breast-feeding, or not using adequate contraception when able to have children
- Lung transplant, or on the waiting list for a lung transplant
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Male or female patients, aged ≥12 years with a confirmed diagnosis of Cystic Fibrosis and persistent Staphylococcus aureus (including MRSA) infection (≥3 positive culture of Staphylococcus aureus (including MRSA) in sputum within the 24 months prior to enrollment)
- Patients with FEV1 ≥ 50% and ≤ 90% of predicted
- Patients able to understand the nature of the study and willing to comply with the protocol requirements
- Patients who (or if < 18 years of age, whose guardians) have signed written informed consent to participate to the study after benefits and risks have been fully explained
Who cannot take part
- Patients with known episodes of bronchoconstriction after drug inhalation
- Ongoing or prior participation in an investigational drug study within 28 days of the Screening Visit. A washout period of 5 terminal half-lives of the previous investigational study drug, or 28 days, whichever is longer, must elapse before the Screening Visit
- Patients under treatment with Kaftrio+Kalydeco for less than 6 consecutive months
- Patients lung transplanted and on the waiting list for lung transplantation
- Patients treated with nebulized or systemic vancomycin or teicoplanin within 8 weeks before the study enrollment
- Patients with chronic Pseudomonas aeruginosa and Bulkholderia cepacia infections will be excluded from the study because it is known that these pathogens cause progressive loss of lung function and requires the administration of inhaled antibiotics. Patients with colonization by others Gram – are instead elegible
- Patients with medical history of hemoptysis (> 300 cc in 30 days)
- Patients with known or suspected allergy or hypersensitivity to glycopeptides or other antibiotics or to any of the excipients
- Abnormal laboratory findings or other findings or medical history at Screening that, in the Investigator's opinion, would compromise the safety of the subject or the quality of the study data
- Patients with decreased liver function (AST or ALT > 3 times higher in comparison to reference values)
- Patients with renal insufficiency (those with eGFR < 15 mL/min/1.73 sqm calculated using the Schwartz formula, which then correspond to CKD V)
- Female patients of childbearing age (less than 24 months after the last menstrual cycle) who do not use adequate contraception. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient
- Female patients who are pregnant or breast-feeding or who wish to become pregnant during the period of the clinical study and for one months later
- Patients with inability to tolerate inhaled products
This trial is currently available in Italy.
- Fondazione IRCCS Cà Granda Ospedale Maggiore PoliclinicoMilan, ItalyTaking people
- Azienda Ospedaliera Universitaria Integrata VeronaVerona, ItalyTaking people
About the trial
What the trial wants to find out
The primary objective of the study is to determine the safety and tolerability of inhaled teicoplanin in patients suffering from cystic fibrosis associated to persistent Staphylococcus aureus (including MRSA) infection treated with the drug at a dosage of 200 mg/3ml BID for two cycles of 28 days separated by 28 days without treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An open-label study to evaluate the safety and tolerability of inhaled Teicoplanin in the treatment of Staphylococcus aureus (including mrsa) infections in cystic fibrosis patients
- Plain-language title
- Tests inhaled teicoplanin for staph infections in people with cystic fibrosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 7 October 2024